Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 7/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.69 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | BLM | P54132 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836188 | 1.00 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL4784530 | 0.98 | ADRA2A (0.67) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| Hydrochloric Acid SCHEMBL1815110 | 0.83 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL4868561 | 0.82 | ADRA2A (0.66) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL11992119 | 0.80 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL1819427 | 0.79 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL13188558 | 0.77 | SLC6A2 (0.52) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL2990957 | 0.77 | TSHR (0.65) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL12610425 | 0.77 | TSHR (0.65) | ADRA2AADRA2BADRA2CADRB1ADRB3 | |
| SCHEMBL30295406 | 0.77 | TSHR (0.65) | ADRA2AADRA2BADRA2CADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896022-B1 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT PHARMACEUTICALS LTD (NZ) | 2012-10-31 | — | — | EP | claimed |
| US-20090215811-A1 | Novel Pharmaceutical Composition and Its Use in a Method For Treatment of Patients With Upper Respiratory Mucosal Congestion | AFT PHARMACEUTICALS LIMITED | 2009-08-27 | — | — | US | claimed |
| EP-1896022-A4 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT PHARMACEUTICALS LTD (NZ) | 2008-08-06 | — | — | EP | claimed |
| EP-1896022-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT Pharmaceuticals Limited (NZ) | 2008-03-12 | — | — | EP | claimed |
| WO-2006135254-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT PHARMACEUTICALS LIMITED (NZ) | 2006-12-21 | — | — | WO | claimed |
| EP-4365193-A1 | CHIMERIC POLYPEPTIDE FOR REGULATING CELL PHYSIOLOGICAL ACTIVITY | Carsgen Therapeutics Co., Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| CN-106323794-A | Method for detecting process stability of gallbladder warming tablets | 广州中医药大学第附属医院 | 2017-01-11 | — | — | CN | disclosed |
| US-8603523-B2 | Pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion | AFT PHARMACEUTICALS LIMITED (NZ) | 2013-12-10 | — | — | US | disclosed |
| US-8603523-B2 | Pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion | AFT PHARMACEUTICALS LIMITED (NZ) | 2013-12-10 | — | — | US | disclosed |
| US-8455692-B2 | Process for resolution of 1-(3-hydroxyphenyl)-2-methylamino ethanol | Divi's Laboratories, Ltd. (IN) | 2013-06-04 | — | — | US | disclosed |
| EP-1896022-B1 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT PHARMACEUTICALS LTD (NZ) | 2012-10-31 | — | — | EP | disclosed |
| US-20120108848-A1 | PROCESS FOR RESOLUTION OF 1-(3-HYDROXYPHENYL)-2-METHYLAMINO ETHANOL | DIVI'S LABORATORIES LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| EP-1896022-A4 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT PHARMACEUTICALS LTD (NZ) | 2008-08-06 | — | — | EP | disclosed |
| EP-1896022-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT Pharmaceuticals Limited (NZ) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896022-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT Pharmaceuticals Limited (NZ) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006135254-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT PHARMACEUTICALS LIMITED (NZ) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135254-A1 | NOVEL PHARMACEUTICAL COMPOSITION AND ITS USE IN A METHOD FOR TREATMENT OF PATIENTS WITH UPPER RESPIRATORY MUCOSAL CONGESTION | AFT PHARMACEUTICALS LIMITED (NZ) | 2006-12-21 | — | — | WO | disclosed |
| US-6900203-B2 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | POLIUM TECHNOLOGIES, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040002549-A1 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-01 | — | — | US | disclosed |
| US-20030055036-A1 | Method for treating a demyelinating condition | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002549-A1 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | ACHE, ALKBH3, BCHE | ADRA2A 1296/4885ADRA2B 944/4885ADRA2C 681/4885 |
| US-20120108848-A1 | PROCESS FOR RESOLUTION OF 1-(3-HYDROXYPHENYL)-2-METHYLAMINO ETHANOL | ADH1A, CYP2E1, ADH1C | ADRA2A 238/4885ADRA2B 357/4885ADRA2C 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.